Slide 1: Regulation 30 disclosure cover letter
Wanbury lnfotech Pvt. Ltd. Re!Jd. Office : BSEL Tech Park, B-wing 10 Floor, Sector-30 A, Opp. Vashi Railway Station, Vashi Navi Mumbai 400 703 Maharashtra, INDIA Tel. : +91-22-6794 2222 Fax : +91-22-6794 2111/333 WAN BURY Website : www.wanbury.com July 01, 2026 To To BSE Limited National Stock Excha
Slide 2: Towards Better Healthcare: Earnings Presentation Q4 & FY26
Towards Better Healthcare Earnings Presentation Q4 & FY26 | July 2026 Wanbury Limited NSE: WANBURY | BSE: 524212 Bloomberg: WANB:IN
Slide 3: Inside this Presentation
Inside this Presentation Company Profile Business Profile Financial Profile Company Profile Business Profile Financial Profile API Business Formulations Business Executive Summary 04 API Business Formulations Business Key Performance Indicators 31 Corporate Journey Strategically Curated 14 Re-Buildi
Slide 4: Company Profile
Executive Summary 04 Corporate Journey 05 Successful Business Turnaround 06 Wanbury at a Glance 07 Business Streams Company 08 Board of Directors 09 Senior Leadership 10 R&D Capabilities 11 Profile Environment, Health & Safety 12
Slide 5: Executive Summary
01 / CO MP ANY P R O FI LE Executive Summary Successful Global market Building new De-risked & turnaround to leaderships in growth drivers in robust balance growth momentum key products API business sheet Operational & financial Globally significant Through launch of an Refinanced debt & healthy tur
Slide 6: Corporate Journey
01 / CO MP ANY P R O FI LE Corporate Journey 1990-2000 2000-2010 2010-2023 2024-Onwards 1990-2000 2000-2010 2010-2023 2024-Onwards Foundation Early Strategic Acquisitions Corporateinto Venture Consolidation Developed Markets Challenges Business Turnaround Transformation Growth Foundation & Early Str
Slide 7: Successful Business Turnaround
01 / CO MP ANY P R O FI LE Successful Business Turnaround Financial Turnaround Operational Turnaround Debt reduction: ~75% reduction from peak- Capacity ramp-up in key existing API debt obligation of ~700 Crores, including products through de-bottlenecking: corporate guarantee from Wanbury Limited M
Slide 8: Wanbury at a Glance
01 / CO MP ANY P R O FI LE Wanbury at a Glance 6 products, 10+ brands, 2 USFDA 100% chronic acute & approved API portfolio semi-chronic facilities Formulations Portfolio with 386 KL cumulative API Portfolio reactor capacity 80%+ 1,200+ 37+ years Export top line, with Employee strength Operating hist
Slide 9: Business Streams
01 / CO MP ANY P R O FI LE Business Streams API Formulations API manufacturer building a niche, Rebuilding legacy brand formulations profitable & sustainable business business in India (50%+ Gross contribution margins) 12% 10+ active brands + additional Diversified business stream across launches in
Slide 10: Board of Directors
01 / CO MP ANY P R O FI LE Board of Directors Mr. Mohan Kumar Mr. K. Dr. Anupama Mr. Mridul Mr. Manoj Mr. Pallavur Rayana Chandran Vaidya Mehta Gursahani Sankar Das Promoter & Whole Time Whole Time Director Non Executive Non Executive Non Executive Non Executive Director Independent Woman Independen
Slide 11: R&D Capabilities
01 / CO MP ANY P R O FI LE R&D Capabilities R&D Capabilities API R&D Center Formulations R&D Center Process Optimization: Optimization of synthesis routes for enhanced yields & lowering costs Impurity Control: Advanced analytical techniques aligned with ICH guidelines Analytical Excellence: Location
Slide 12: Environment, Health & Safety
01 / CO MP ANY P R O FI LE Environment, Health & Safety EHS at Wanbury • Best-in-class standards: Committed to • Safety culture: Comprehensive global EHS norms and strict regulatory training, systematic risk compliance across all operations assessments (HAZOP), and robust emergency response systems
Slide 13: Business Profile: API
Strategically Curated 13 Product Portfolio Business World-Class Manufacturing 14 Infrastructure Developed Market 15 Profile: Focused Business Profile Regulatory Approvals 16 Manufacturing Capabilities 17 Strategy & Way Forward API 18 Safety First Culture 19
Slide 14: API: Strategically Curated Product Portfolio
02 / B US INE S S PR O F ILE : AP I API: Strategically Curated Product Portfolio Significant global market share in Top 3 products Molecule Therapeutic Category Global Market (MT) Estimated Market Share Metformin Antidiabetic ~75,000 ~10% Sertraline Antidepressant ~680 ~30% Tramadol Pain Management
Slide 15: API: World-Class Manufacturing Infrastructure
02 / B US INE S S PR O F ILE : AP I API: World-Class Manufacturing Infrastructure Cumulative installed Site 1: Tanuku, Andhra Pradesh Site 2: Patalganga, Maharashtra reactor capacity: 500 KL Future reactor capacity potential at existing sites: 600 KL 400 KL Multi-Purpose Plant 96 KL Dedicated Plant
Slide 16: API: Developed Market Focused Business Profile
02 / B US INE S S PR O F ILE : AP I API: Developed Market Focused Business Profile Focused on regulated markets Exporting to 50+ countries Exporting to 4+ continents Total Revenue Mix 20% 80% Exports Domestic Map not to scale, only for illustration purpose. Investor Presentation | Wanbury Limited 15
Slide 17: API: Regulatory Credentials For Both Sites
02 / B US INE S S PR O F ILE : AP I API: Regulatory Credentials For Both Sites EU Written WHO GMP confirmation US – FDA Europe – EDQM Brazil – ANVISA South Korea – KFDA Mexico – COFEPRIS Approval since Approval since Approval since 2000 Approval since 2007 Approval since 2024 Approval since 2012 App
Slide 18: API: Manufacturing Capabilities
02 / B US INE S S PR O F ILE : AP I API: Manufacturing Capabilities Chemistry Reaction System Capabilities Capabilities Capabilities • Azidation • High Pressure Reactions • Deployed SAP S4 HANA • Bromination • High Vacuum Distillations • Dedicated software for Sales & • Cyanation • Direct Compressio
Slide 19: API: Strategy & Way Forward
02 / B US INE S S PR O F ILE : AP I API: Strategy & Way Forward Product Selection Framework Way Forward Mid-Size Molecules Targeted expansion in regulated markets (US, EU, Brazil) – new & existing molecules Small-to-Mid size molecules + Aim double- digit market share 4 commercial launches of new mol
Slide 20: API: Safety First Culture
03 / B US INE S S PR O F ILE : FO R MU LAT IO NS API: Safety First Culture Investor Presentation | Wanbury Limited 19
Slide 21: Business Profile: Formulations
Re-Building Business 21 Business Brand Portfolio 22 Strategy & Way Forward 23 Profile: Formulations
Slide 22: Formulations: Re-Building Business
03 / B US INE S S PR O F ILE : FO R MU LAT IO NS Formulations: Re-Building Business Formulations - Revenue & Share Overview • Formulations business journey 13% 12% 12% commenced in 1995 with the 11% acquisition of Wander Ltd, formerly a 10% division of Sandoz • Current portfolio is focused on therap
Slide 23: Formulations: Brand Portfolio
03 / B US INE S S PR O F ILE : FO R MU LAT IO NS Formulations: Brand Portfolio Top brands Anti Cold & Cough Pain & Inflammation, Antacids & Anti-ulcerants Herbal Laxative Muscular Spasm Protein Supplement Calcium Supplement - Nutritional Supplement Multivitamin Supplement Osteoporosis & Bone Health
Slide 24: Formulations: Strategy & Way Forward
03 / B US INE S S PR O F ILE : FO R MU LAT IO NS Formulations: Strategy & Way Forward Operational Objectives Strategic Way Forward Leverage 3+ decades of heritage to re-build a 1 Latest brand launch (FY25) scalable branded formulations franchise C RED (Iron Supplement) Transition portfolio from acut
Slide 25: Q4 & FY26 Earnings Update
Performance Highlights 25 Business Vertical Performance Q4 & FY26 26 P&L Snapshot 27 Management Commentary 28 Earnings Update
Slide 26: Q4 & FY26 Performance Highlights
0 4 / Q 4 & FY 2 6 E A R N IN GS U PD A T E Q4 & FY26 Performance Highlights Revenue (in ₹ Crore) 172 650 162 165 (4%) 8% 600 YOY GROWTH YOY GROWTH Q4FY25 Q3FY26 Q4FY26 FY25 FY26 EBITDA (in ₹ Crore) 31 30 108 27 80 (4%) 35% YOY GROWTH YOY GROWTH Q4FY25 Q3FY26 Q4FY26 FY25 FY26 PAT (in ₹ Crore) 20 22
Slide 27: Business Vertical Performance
0 4 / Q 4 & FY 2 6 E A R N IN GS U PD A T E Business Vertical Performance API - Revenue (in ₹ Crore) 150 574 144 530 141 (4%) 8% YOY GROWTH YOY GROWTH Q4FY25 Q3FY26 Q4FY26 FY25 FY26 Formulations - Revenue (in ₹ Crore) 22 76 71 17 15 (12%) 7% YOY GROWTH YOY GROWTH Q4FY25 Q3FY26 Q4FY26 FY25 FY26 Inves
Slide 28: Q4 & FY26 P&L Snapshot
0 4 / Q 4 & FY 2 6 E A R N IN GS U PD A T E Q4 & FY26 P&L Snapshot PARTICULARS (in ₹ Crore) Q4FY25 Q3FY26 Q4FY26 YOY Change QOQ Change FY25 FY26 YOY Change Revenue from Operations 172.00 162.45 164.58 1% -4% 599.51 650.27 8% Other Income 1.84 0.18 0.21 16% -89% 3.49 0.94 -73% COGS 83.25 68.80 65.30
Slide 29: Management Commentary
0 4 / Q 4 & FY 2 6 E A R N IN GS U PD A T E Management Commentary “FY26 was an important year for Wanbury. We strengthened business fundamentals through operational efficiencies, debottlenecking, balance sheet improvement, and expansion of our API and formulations portfolio. Improved plant utilisati
Slide 30: Financial Profile
Key Performance Indicators 32 5Y P&L Snapshot 33 5Y Balance Sheet Snapshot 34 5Y Cash Flow Snapshot 35 Financial Capital Markets Overview 36 Profile
Slide 31: Key Performance Indicators
05 1 / FQI N 2 A&N H C1I A F YL 2P6 REOAFRI LNEI N G S U P D A T E Key Performance Indicators Revenue from Gross Profit & EBITDA & PAT & Operations (in ₹ Crore) Gross Margins (in ₹ Crore & in %) EBITDA Margins (in ₹ Crore & in %) PAT Margins (in ₹ Crore & in %) Gross Profit Gross Margin EBITDA EBITD
Slide 32: 5Y P&L Snapshot
0 5 / FI NAN C IA L P R OF IL E 5Y P&L Snapshot PARTICULARS (in ₹ Crore) FY22 FY23 FY24 FY25 FY26 Revenue from Operations 511.2 499.7 575.7 599.51 650.26 Other Income 1.51 0.91 2.99 3.49 0.94 COGS 300.3 303.4 302.6 294.47 276.51 Gross Profit 212.4 197.1 276 308.53 374.70 Gross Margin (%) 42% 39% 48%
Slide 33: 5Y Balance Sheet Snapshot
0 5 / FI NAN C IA L P R OF IL E 5Y Balance Sheet Snapshot PARTICULARS (in ₹ Crore) FY22 FY23 FY24 FY25 FY26 Equity Share Capital Equity Share Capital 32.67 32.7 32.74 32.77 34.94 Other Equity -30.48 -39.96 -4.8 26.5 109.51 Non-Current Liabilities Long Term Borrowings - - 82 160.29 147.15 Others 16.2
Slide 34: 5Y Cash Flow Snapshot
0 5 / FI NAN C IA L P R OF IL E 5Y Cash Flow Snapshot PARTICULARS (in ₹ Crore) FY22 FY23 FY24 FY25 FY26 Cash Flow from Operating Activities 37.56 19.8 4.02 26.1 31.53 Cash Flow from Investing Activities 0.59 -8.84 -16.62 -51.17 -56.40 Cash Flow from Financing Activities -25.62 -31.99 14.55 25.73 22.
Slide 35: Capital Markets Overview
0 5 / FI NAN C IA L P R OF IL E Capital Markets Overview Shareholding Pattern (%) 0.72 Current Market Price ₹271 56.20 43.08 52 Week High/Low ₹321 / ₹162 Market Capitalization ₹948 Crore No. of Shares Outstanding 3.49 Crore NSE WANBURY Promoters Public FIIs + DIIs BSE 524212 Shareholding data as of
Slide 36: Wanbury investor contacts
WAN B URY Ta..v ds Botlor Ht' thcaro iro 'P 1 a J- r'dro c d i Ch.e' Fiior.cial Of cer comoon•1 se cre·ol"Y ·nvesta@wont>urv.com I cs .vort>\Jrv.com ·nvertcrrelotions 110rt>urv.ccm • ( 4 ., TIL Advisors f>rivote Limited Adfoctors PR :i Pokt-orna or nv estor ~e a··ons Advisor °" lr1,.e:; Relo1ions A